<DOC>
	<DOCNO>NCT00378443</DOCNO>
	<brief_summary>IgA nephropathy ( IgAN ) common primary glomerulonephritis worldwide . Since etiology disease clearly understood , specific therapeutic strategy define IgAN . Both ACEi/ARB steroid find effective slow rate disease progression , use steroid restricted side effect . However , evidence RCT question whether combine use steroid ACEi/ARB bring benefit IgAN patient ACEi/ARB alone . We therefore undertook randomize , multicenter study investigate efficacy safety profile combine use ACEi/ARB plus steroid compare ACEi/ARB alone treatment patient IgAN .</brief_summary>
	<brief_title>ACEi/ARB Alone Versus ACEi/ARB Plus Steroids Treatment Primary IgA Nephropathy , RCT</brief_title>
	<detailed_description>IgA nephropathy ( IgAN ) common primary glomerulonephritis worldwide . Since etiology disease clearly understood , specific therapeutic strategy define IgAN . In many study treatment IgAN , ACEi/ARB steroid find effective slow rate disease progression , use steroid restricted side effect , ACEi/ARB consider first line therapy . However , evidence RCT question whether combine use steroid ACEi/ARB bring benefit IgAN patient ACEi/ARB alone . We therefore undertook randomize , multicenter study investigate efficacy safety profile combine use ACEi/ARB plus steroid compare ACEi/ARB alone treatment patient IgAN .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Cilazapril</mesh_term>
	<criteria>1. underwent renal biopsy within 1 year start fo trial ; 2 . 24 hour urinary protein excretion range 1 7 g/d ; 3. eGFR , evaluate MDRD formula , high 30 ml/min 1. crescentic glomerulonephritis ; 2. steroid therapy subject within 1 year trial ; 3. malignant hypertension ( DBP &gt; 130 mmHg and/or SBP &gt; 220mmHg ) , resistant antihypertensive agent ; 4. urinary protein excretion decrease 1 g/l runin period ; 5 . Myocardial infarction cerebrovascular accident 6 month precede trial ; 6. renovascular disease ; 7. diabetes mellitus ; 8 . Malignancy , severe liver disease , refractory infection ; 9. peptic ulcer active disease phase ; 10. pregnancy ; 11. contraindication use ACEi/ ARB corticosteroid ; 12. alcohol abuse drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>